Skip to main content

Table 4 Univariate and multivariate Cox regression analysis on OS and PFS

From: Stereotactic body radiotherapy versus lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity matching score analysis

Variable

OS (N = 76, events = 70)

PFS (N = 76, events = 76)

Univariable model

Multivariable model

Univariable model

Multivariable model

HR (95% CI)

Pa

HR (95% CI)

pa

HR (95% CI)

pa

HR (95% CI)

pa

Group (refer to LEN)

0.54(0.32–0.89)

0.015

0.38(0.22–0.65)

0.000

0.54(0.33–0.87)

0.012

0.46(0.28–0.75)

0.002

Gender (refer to Male)

1.04(054 − 2.00)

0.901

  

1.13(0.60–2.11)

0.702

  

Age (refer to < 55 years)

1.12(0.70–1.80)

0.635

  

1.18(0.75–1.87)

0.476

  

Etiology (refer to HBV)

2.08(0.64–6.74)

0.223

  

2.99(0.91–9.82)

0.071

2.55(0.74–8.78)

0.138

Child-Pugh classification

(refer to A)

1.57(0.67–3.66)

0.297

  

1.28(0.55–2.98)

0.567

  

ECOG PS (refer to 0)

1.39(0.86–2.25)

0.174

  

1.30(0.82–2.06)

0.261

  

Number Of Tumors

(refer to < 3)

3.00(1.77–5.07)

0.000

3.00(1.72–5.26)

0.000

2.75(1.64–4.60)

0.000

2.58(1.51–4.40)

0.001

Tumor size (refer to < 5 cm)

1.41(0.98–2.02)

0.065

1.34(0.91–1.98)

0.136

1.15(0.83–1.59)

0.416

  

PVTT (refer to Vp1)

2.45(1.71–3.50)

0.000

2.39(1.62–3.53)

0.000

1.63(1.21–2.20)

0.001

1.62(1.19–2.20)

0.002

ALBI grade (refer to 1)

1.43(0.87–2.37)

0.164

  

1.34(0.83–2.17)

0.236

  

AFP (refer to ≤ 200 ng/mL)

0.75(0.47–1.22)

0.244

  

0.88(0.56–1.39)

0.586

  

PLT (refer to < 100 × 109/L)

0.68(0.39–1.20)

0.188

  

0.68(0.40–1.17)

0.165

  

WBC (refer to < 4 × 109/L)

0.98(0.56–1.72)

0.945

  

0.97(0.57–1.66)

0.924

  

Previous local treatment

(refer to Absence)

0.73(0.39–1.37)

0.324

  

0.62(0.34–1.13)

0.115

  
  1. HBV, hepatic B virus; HCV, hepatic C virus; ECOG, Eastern Cooperative Oncology Group; PS, performance status; MVI, macrovascular invasion; ALBI, grade albumin-bilirubin grade; AFP, alpha-fetoprotein; PLT, platelet; WBC, white blood cell; LEN, lenvatinib; TAE, transcatheter arterial embolization; SBRT, Stereotactic Body Radiotherapy; LEN, lenvatinib. PFS, progression-free survival; OS, overall survival; IHPFS, intrahepatic progression-free survival
  2. a Bold values indicate statistical significance